Fig. 3

Highly expressed miR-744 in cancer cell-derived EVs represses NSCLC development in vitro. a Expression of miR-744 determined by RT-qPCR in H1299 and H522 cells transfected with miR-744 mimic (* p < 0.05 vs. H1299 or H522 cells transfected with mimic-NC). b Expression of miR-744 determined by RT-qPCR in EVs derived from H1299 or H522 cells treated with miR-744 mimic (* p < 0.05 vs. EVs derived from H1299 or H522 cells transfected with mimic-NC). c Expression of miR-744 determined by RT-qPCR in A549 and H460 cells treated with EVs derived from H1299 or H522 cells treated with miR-744 mimic. d CCK-8 proliferation assay evaluating the viability of A549 and H460 cells treated with EVs derived from untreated H1299 or H522 cells or H1299 or H522 cells transfected with miR-744 mimic. e Colony formation assay detecting the colony formation of A549 and H460 cells treated with EVs derived from H1299 or H522 cells transfected with miR-744 mimic. f Flow cytometry analysis showing the cell cycle distribution of A549 and H460 cells treated with EVs derived from H1299 or H522 cells transfected with miR-744 mimic (* p < 0.05, vs. A549 and H460 cells treated with EVs from H1299 cells transfected with mimic-NC; # p < 0.05, vs. A549 and H460 cells treated with EVs from H522 cells transfected with mimic-NC). Data are summarized as mean ± standard deviation of three technical replicates. Data from two groups were compared using unpaired t-test and data from multiple groups were assessed by one-way ANOVA with Tukey's post hoc tests. Data obtained at different time points were analyzed by Bonferroni-corrected repeated measures ANOVA